Ventura Clinical Trials, Malibu, CA, USA.
J Int Med Res. 2020 Jun;48(6):300060520925930. doi: 10.1177/0300060520925930.
Alzheimer's disease (AD), the most common form of dementia, is a leading cause of death and a major cause of morbidity in older people. The disease is characterized by progressive memory loss, cognitive impairment, and the cerebral accumulation of amyloid-β peptide. Given the health and economic impacts of AD, treatments that target the underlying etiology of AD or modify the course of the disease are of significant interest. The gut microbiome has been increasingly implicated in the pathogenesis of several neurological diseases, including multiple sclerosis and Parkinson's disease. Furthermore, emerging evidence has demonstrated that there are alterations in gut microbiome composition in patients with AD, suggesting involvement of the microbiome-gut-brain axis. We present symptom improvement in a patient with AD following fecal microbiota transplantation for a infection.
阿尔茨海默病(AD)是最常见的痴呆症形式,是老年人死亡的主要原因之一,也是发病率的主要原因。该疾病的特征是进行性记忆丧失、认知障碍和大脑中淀粉样β肽的积累。鉴于 AD 的健康和经济影响,针对 AD 根本病因或改变疾病进程的治疗方法具有重要意义。肠道微生物组越来越多地与包括多发性硬化症和帕金森病在内的几种神经疾病的发病机制有关。此外,新出现的证据表明,AD 患者的肠道微生物组组成发生了改变,这表明微生物组-肠道-大脑轴的参与。我们提出了一例 AD 患者在接受粪菌移植治疗 感染后症状改善的病例。